IFCT-2103 DIAL
What it tests: Continuing pembrolizumab (± pemetrexed) up to 2 years vs stopping (observation) in metastatic NSCLC with disease control at 6 months
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.